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COGNITIVE RESERVE AND THE CLINICAL MANIFESTATIONS OF 
CHRONIC TRAUMATIC ENCEPHALOPATHY 
KYLE FRANK 
ABSTRACT 
 Chronic Traumatic Encephalopathy (CTE) is a neuropathological disease that has 
been associated with contact sports involving repetitive brain injury. This disease is 
becoming more well-known due to an increase in media coverage, most notably for its 
possible association with professional football players. This has led to growing concern 
for the risks of participating in contact sports and the need for further research. There still 
remains much to be learned about this neurodegenerative disease. The current 
understanding of the epidemiology and risk factors for this disease are limited by biases 
in methodology, generalizability, and the use of retrospective data. The only method to 
diagnose CTE is via autopsy, which has contributed to some of these limitations. The 
pathogenesis of the disease involves hyper-phosphorylated (p-tau) tau accumulation in 
distinct areas in the cerebral cortex, leading to neuronal disfunction. The most accepted 
risk factor for this disease is recurrent brain trauma. Clinically, it can present with 
varying cognitive, mood, and behavior symptoms and different ages of onset, which often 
leads to a misdiagnosis of other neurodegenerative diseases. There are a few proposed 
treatments for CTE but more clinical trials must be performed before any are accepted in 
clinical practice.  
	
	 v 
 One potential modifying factor for CTE symptomology is cognitive reserve (CR).  
CR is an individual brain’s ability to cope with insults such as neuropathological disease, 
trauma, and the normal ageing process. Higher CR has shown to have a positive effect on 
other neuropathologies such as Alzheimer’s Disease (AD). This led to a preliminary 
study of CR which showed that one measure of CR, occupational attainment, was 
associated with delayed onset of symptoms of CTE.  
Our study builds upon this preliminary study by also examining the effect of CR 
on clinical symptoms of CTE. We expand on this study by using a previously validated 
tool to measure CR, including aspects such as education, occupational attainment, and 
social/leisure activities. Our study also includes subjects from other contact sports at 
varying levels of participation.  
The results of our study will provide a better understanding of the relationship 
between CR and clinical symptoms of CTE. This will allow future research to build upon 
these results and continue to advance our knowledge of this disease.  These advances 
allow changes to be made in clinical practice and athletic organizations in order to 
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Chronic Traumatic Encephalopathy (CTE) was first described in 1928 by Harrison 
Martland who referred to the condition as “punch drunk.” He observed progressive 
mental and physical deterioration in boxers who had a history of sustaining a significant 
amount of repetitive brain trauma.1 This condition was studied primarily in boxers until 
the early 2000’s when CTE was identified in other athletes with a history of repetitive 
brain injury, including those playing football, hockey, rugby, soccer and wrestling, and in 
military personnel exposed to blast injury.2 3 Pathological findings of CTE in participants 
of these other popular sports led to significant attention both from the medical 
community and the media. Omalu and his colleagues were the first to report CTE in 
professional football players in 2005-2006 in a series of case-reports.4 5 In July of 2017 
the Journal of American Medical Association (JAMA) posted the results of a study by 
Anne McKee at Boston University. This study reported of pathological findings of CTE 
in 110 out of 111 participants who had played in the National Football League, becoming 
the largest study to demonstrate pathological findings of CTE at the time. While the study 
received substantial media coverage, it had many limitations noted by other researchers,6 
highlighting the need for further research in this field of neuropathology. Due to the large 
number of athletes engaging in these contact sports at varying ages and the fear of long-




CTE is a neuropathological disease defined by the abnormal accumulation of 
hyperphosphorylated tau in distinct patterns throughout the brain and has been found to 
be associated with repetitive brain trauma.7 8 9 The disease manifests as one or a 
combination of two different clinical variants.  The first variant usually presents younger 
and with initial mood/behavioral symptoms, which eventually progresses to cognitive 
impairment. The second variant presents at a later age with the onset of cognitive 
impairments.10 However, it is important to note that these symptoms vary greatly between 
individuals and often resemble other neurodegenerative disease.6 Diagnosis is made 
through the identification of specific neuropathologic findings during autopsy of the 
brain.8 Researches are currently looking to advance this method by using different 
techniques to diagnosis CTE in vivo such as using serum biomarkers and different 
imaging modalities.11 12 There is no current consensus on how to treat CTE. Strategies 
involving non-steroidal anti-inflammatory drugs (NSAIDs) and other drugs have been 
proposed for treatment but further investigation on their efficacy is warranted.13 Many 
risk factors for the development of CTE have been explored, including genetic 
susceptibility14 and exposure to mild traumatic brain injury (MTBI),7 but there is 
contradicting research for both of these claims. While football is the most common 
contact sport associated with the development of neurogenerative disease and CTE, a few 
recent studies about exposure to high school football have results showing no such 
correlation.15 16 One study looking at exposure to football at a young age did not yield 
any worse cognitive outcomes or symptoms, when compared to healthy controls.17 The 
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results of these studies further support the need for better investigation on the risk factors 
for this disease. 
 
Statement of the Problem 
CTE is becoming a larger public health problem due to the  number of individuals 
participating in contact sports that involve repetitive brain injury and the growing concern 
that this may have long-term consequences. More people are aware of this disease due to 
the recent increase in media coverage, books about the disease, and even movies. 
However, more research needs to be done on CTE before drastic changes to contact 
sports need to be made. A review paper in 2018 by Schwab highlights many of the 
limitations and biases in this field. One of these limitations includes insufficient evidence 
for risk factors, such as repetitive brain injury, in developing CTE. 6 Andrew Gardner 
published a meta-analysis also stating the scientific research on CTE is still premature. 
He also agrees that the causal relationships between sub-concussive brain injury and CTE 
may not be as strong as it is portrayed to be. 18 Before this causal assumption can be 
made, additional research is still needed in many areas, including moderator variables 
that may affect the relationship between the neuropathology of CTE and its clinical 
symptoms.  
Cognitive reserve is one factor that may moderate the effect of CTE 
neuropathology and symptomology. Cognitive reserve (CR) is a brain’s ability to respond 
to pathological insult due to a pre-existing cognitive process or compensatory 
mechanism.19 CR has been estimated using many different measures, including education 
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attainment, occupational attainment, socioeconomic status, literacy, IQ, and leisure 
activities. Higher CR has been shown to delay onset of symptoms in Alzheimer’s disease 
(AD), a neuropathological disease similar to CTE.20 However, only one study has 
investigated the potential effect of CR on CTE. This study found that one measure of CR, 
occupational attainment, was associated with a delayed onset of symptoms of CTE by an 
average of 10 years. However, this study was limited in its sample size, a small group of 
American professional football players, and only looked at the associations with two 
measures of CR.21  
 
Hypothesis 
Male subjects with a confirmed case of pathological CTE on autopsy with a higher CR 
score will experience later onset and less severe clinical symptoms of CTE than subjects 
with a lower score, using the Lifetime of Experiences Questionnaire (LEQ) as a 
measurement for CR. 
	
Objectives and specific aims 
This study will examine the relationship between cognitive reserve and Chronic 
Traumatic Encephalopathy. Specifically, our study will investigate whether a higher level 
of CR, measured via multiple proxies, is associated with delayed symptom onset and/or 
less severe symptoms in former athletes who have been diagnosed with CTE on autopsy. 
This will expand upon a preliminary examination of this relationship which found that 
increased occupational attainment, one measure of CR, is associated with a delay in 
clinical symptoms of CTE in former professional football players. Our study will better 
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characterize the effect of this potential moderator variable on the clinical development of 
CTE. The specific aims for this study are to:  
• Quantify the level of CR in different athletes from varying sports. 
• Demonstrate a correlation between CR and its effect on CTE symptom onset. 




REVIEW OF THE LITERATURE 
Overview of Research Topic 
 
History of CTE 
 
The first description of Chronic Traumatic Encephalopathy was by Harrison 
Martland in 1928. He described a condition called “punch drunk”, which he observed 
most often affected boxers who suffered considerable amount of head trauma while 
fighting. 1 Martland noted symptoms in these fighters began as mild in nature but, in 
severe cases, progressed to marked mental and physical deterioration. He found that 
almost 50 percent of boxers suffered from this condition and many of them had 
associated neurobehavioral symptoms. Almost ten years after Martland’s initial 
observations of this disease, Millspaugh introduced a term to replace “punch drunk,” 
“dementia pugilistica” which was less mocking to boxers.22  He suggested that there was 
cumulative damage from acute injury mechanisms, particularly to the corpora striata, 
corona radiata, and the basal ganglia. Later, Courville termed the condition “psychopathic 
deterioration of pugilists.”7 In 1957 Critchley created the term that is most similar to 
today’s, “chronic progressive traumatic encephalopathy of boxers,” after finding 69 cases 
of a progressive neurological disease in former boxers.23. In the early 2000’s, CTE was 
identified in other professional athletes with a history of brain injury in other contact 
sports, such as football, hockey, wrestling, and rugby.2 3 It was also discovered in 
military personnel that experienced head trauma from explosions.24 25 The first 
confirmation of a football player with CTE was in 2005 by Omalu. He published the 
results of an autopsy in the Journal of Neurosurgery (JNS), presenting a case of a retired 
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professional football player whose brain showed pathological changes consistent with 
CTE.26 Omalu published a second report the following year of another professional 
football player showing pathological evidence of CTE on autopsy.27 The largest study 
thus far of neuropathological findings of CTE in American football players was in 
2017.28 In this study, Mckee analyzed the brains of 202 deceased football players varying 
from high school to professional level. She found neuropathological evidence of CTE in 
177 of 202 brains, which included 110 of 111 in the professional football player group. 
One limitation of this study was an ascertainment bias, which may have led to a 
misrepresentation of the true frequency of the disease. However, this study gained much 
attention from the public and has increased the need for further research on CTE to 
determine the true prevalence of this disease in athletes of contact sports. 
   
Epidemiology and Risk Factors 
Currently, the true prevalence of CTE in athletes and its strength of association 
with MTBI is unknown. These factors have been difficult to measure for a variety of 
reasons. One study in 2015 outlined many of these challenges, which includes recall bias, 
selection bias, lack of consensus clinical criteria for CTE, cohort effects, and secular 
trends.29 The most widely accepted way to diagnose and characterize the severity of CTE 
is by neuropathological evidence on autopsy. Autopsy reports have shown prevalence of 
CTE in football players ranging from 50%-99% 9 30 31with the largest study finding 
neuropathological evidence of CTE in 88% of the brains of former football players.32 
This has led to the general assumption that playing football increases risk for CTE and 
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other neurodegenerative diseases. However, the true prevalence of the disease is difficult 
to accurately measure due to ascertainment bias and lack of healthy controls in these 
studies. One study out of the Mayo Clinic assessed the risk of developing 
neurodegenerative disease later in life due to exposure to high school football. The results 
showed no increased risk among 438 football players when compared to controls.16  
There is evidence supporting several risk factors in the development of CTE. One 
is increasing age, which has also been found to contribute to the development of other 
neurodegenerative diseases such as dementia and Parkinson’s disease.9 33 Other possible 
risk factors for CTE are repetitive MTBI34, repetitive sub-concussive head trauma35, and 
increased duration of exposure to contact sports. Another study by McKee in 2013 on the 
brains of 58 football players found pathological evidence of CTE in 42 subjects. Of these 
subjects, 35 families were available for interviews regarding the subjects’ exposure. This 
study found that the number of years playing football, the number of years since 
retirement, and age at death were all significantly correlated with a higher stage of CTE 
diagnosed on autopsy.9 This study suggested that increased exposure to football was a 
risk factor for the development of a more severe stage of CTE. However, Mckee’s study 
did not contain any healthy controls for comparison. In a more recent study of 211 former 
tackle football players the authors found potentially conflicting results. In this study they 
observed no association between CTE pathological severity with age of first exposure 
(AFE) to playing football.36 Another study published in the New Zealand Journal of 
Sports Medicine (NZJSM) analyzed the risks of playing football on cognitive impairment 
and depression later in life using 834 males who participated in high school football. 
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They found that playing football was not associated with cognitive impairment or 
depression later in life and there was no difference in the incidence of neurodegenerative 
disease when compared to their classmates who did not play football.15 Overall, these 
studies show that it cannot be concluded that increased exposure to contact sports, even 
football, results in a higher risk of developing CTE. 
Another risk factor is a genetic pre-disposition to CTE. Specifically, researchers 
have looked at the effects of alleles of Apolipoprotein E4, a protein used for cholesterol 
transport, on susceptibility to tauopathy and CTE. The APOE e4 allele has been studied 
extensively and has been linked to the development of Alzheimer’s disease (AD).37 38 
Due to pathological similarities between AD and CTE,39 research has focused on 
determining whether this allele can also be a risk factor for developing CTE later in life.  
The 2013 study by Mckee did not find a significant association in individuals diagnosed 
with CTE carrying the ApoE e4 allele compared to the general population.9 However, 
like most current studies on CTE, the sample size was small (n=68) and so it cannot be 
completely dismissed as a potential risk factor for CTE.  
 
Pathogenesis 
The pathogenesis of CTE involves the deposition of hyper-phosphorylated tau (p-
tau) and neurofibrillary tangles (NFTs) in distinct patterns throughout the cerebral cortex. 
Tau is a protein that helps stabilize the axons of neurons through a process of 
phosphorylation, a chemical addition of a phosphoryl group. Traumatic brain injury 
(TBI) can lead to the disconnection of tau from the axons resulting in the formation of 
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NFTs. Eventually this process of NFT accumulation and hyper-phosphorylation of tau 
leads to a disruption in the normal communication between neurons. 40 Another key 
component in the pathogenesis is microglial and astrocytic activation in response to brain 
injury. This activation creates an inflammatory response to the trauma which can 
eventually lead to cell death and neurotoxicity.41 
The pathogenesis of CTE is closely related to that of pathogenesis of Alzheimer’s 
Disease (AD), which also consists of p-tau and NF tangle deposition. However, there are 
some key distinctions in the pathologies highlighted in a study by Turner et al.39 In 
general, AD results in more cerebral atrophy and deposition of amyloid plaques. 
Additionally, the diseases have different distribution patterns of NFTs. In CTE, NFT 
deposition is usually confined to the more superficial layers and/or located within the 
cerebral vasculature. Deposition also tends to be seen in Ammon’s horn and in the 
substantia nigra, which are two uncommon areas for NFT accumulation in AD. For AD, 
the NF tangle deposition is usually confined to the deeper cortex layers and found mostly 
in the CA1 area of the brain. While the pathologies of these two diseases usually follow 
these distinct patterns, it isn’t always one or the other. Turner also described a case in 
which a patient had both CTE and AD pathology, showing that it is possible for someone 
to be suffering from both diseases concurrently.   
 
Diagnosis 
In 2016 the National Institute of Neurological Disorders and Stroke (NINDS) and the 
National Institute of Biomedical Imaging and Bioengineering (NIBIB) formed a panel of 
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7 neuropathologists to blindly evaluate many different tauopathies including CTE.8 Upon 
the conclusion of this study the pathologists came to an agreement for the diagnosis of 
CTE. They defined CTE as an accumulation of abnormal hyperphosphorylated tau (p-tau) 
and NFTs in neurons and astrocytes. These accumulations are distributed around small 
blood vessels at various depths and in an irregular patterns within the cerebral cortex.  
Like many other neurodegenerative diseases, the definitive diagnosis of CTE can 
only be made post-mortem via autopsy. In 2012, Ann McKee categorized CTE into 4 
stages based on gross and microscopic pathology findings of the brain (Figure 1).9 Stage I 
CTE pathology is defined by p-tau astrocytic tangles and NF tangles that are located 
around the cerebral vasculature. Stage II is defined by cortical deposition of p-tau and is 
located deeper in the cerebral sulci. Stage III CTE pathology includes spread of p-tau 
tangles into the subpial and periventricular regions as well as the diencephalon, basal 
ganglia, and brainstem. Stage IV is characterized by NF tangles that are mostly located in 
the superficial regions of the cerebral cortex. This is most current method of staging CTE 





Figure 1: Pathological Stages of CTE (adapted from Mckee 2012)9 
This shows the four stages of CTE characterized by distinct pathological findings. The 
gross findings of cerebral atrophy and abnormal p-tau accumulation in different patterns 
throughout the cortex shown here is characteristic of CTE pathology.  
 
There are many methods currently being tested to aid in the diagnosis of CTE in 
vivo, including Positron Emission Tomography (PET) scans, Magnetic Resonance 
Imaging (MRI), Diffusion Tensor Imaging (DTI) and serum/cerebral spinal fluid (CSF) 
biomarkers. One of the most recent biomarkers being investigated for use in the diagnosis 
of CTE is CCL11, also known as eotaxin-1. This biomarker is a chemokine previously 
found to be involved in pathways that contribute to allergic inflammation, inflammatory 
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bowel disease, and asthma.11 CCL11 is primarily produced by the peripheral immune 
system but, recently, has been found to be produced directly from the choroid plexus of 
the brain in mice.42 Additionally, non-neuronal cells in the brain, such as astrocytes, 
oligondrocytes, and microglia, have been found to express receptors that respond directly 
to CCL11, suggesting a function of this chemokine in the central nervous system.43 A 
study by Cherry et al. in 2017  found that CCL11 levels in the CSF were significantly 
elevated in former American football players with autopsy confirmed CTE compared to 
controls.11 They also analyzed individuals with AD in this study and did not find elevated 
CCL11. The study was limited by a small sample size but the results still suggest 
potential utility in  diagnosing CTE in a living patient. It can be one of many biomarkers 
used to discriminate CTE from AD and aid in the diagnosis of CTE in a person with a 
history of repetitive brain injury.  
Another technique that is being investigated for use in the detection of CTE in 
living patients is DTI. This type of imaging is similar to an MRI but measures the 
directional diffusion of water and is more sensitive in detecting microstructural damage 
to axons. This ability to detect small changes in the white matter tracts of the brain allows 
it to be a reliable way to visualize differences in patients with a history of a MTBI.44 
However, recent studies have found conflicting results when looking at acute and chronic 
changes in DTI imaging in patients with MTBI and thus cannot be used as a reliable 
diagnostic tool yet. 12  
Finally, one of the more recent imaging techniques being studied for the in vivo 
diagnosis of CTE is PET scans, a type of nuclear medicine tool. It uses a radioactive 
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substance in order to visualize the metabolism of a particular tissue in the body. More 
specifically, researchers and clinicians design radiotracers that are specific to either 
mimic certain endogenous compounds or binds to a specific endogenous protein. These 
radiotracers then emit positrons which undergo radioactive decay and eventually produce 
photons. These photons are then able to be captured by the PET scanner and clinicians 
can view them in real time. Currently researchers are attempting to design a radioactive 
tracer that binds to p-tau, the protein that accumulates in the pathogenesis of CTE, with 
many challenges. The tracer needs to be highly specific, have high affinity for p-tau, and 
be able to cross the blood-brain barrier. 12  
In summary, even though the diagnosis of CTE can only be made post-mortem 
via autopsy, there are many studies currently working on effective ways to diagnosis 
people in vivo. Due to the overlap in pathogenesis of CTE with other neurodegenerative 
diseases and the potential for false positives in some of these modalities, it is likely that 
the ability to do this will require more than one test. 
 
Clinical Presentation 
A study done by Stern et. al in 2013 found that there are two major initial clinical 
presentations of CTE in athletes.10 One is with cognitive deficits and the other is with 
behavioral/mood changes. The study included 33 total athletes from multiple sports 
including football, hockey, boxing, and wrestling. One-third of these athletes (N=11) 
initially presented with cognitive impairment including different combinations of 
memory impairment, executive dysfunction, attention and concentration difficulties, 
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language impairment and visuospatial difficulties. This group first presented with clinical 
symptoms at the average age of 54.5. The rest of the athletes (22 total) initially presented 
at a mean age of 34.5 years old with behavioral or mood changes such as explosivity, 
impulsivity, physical violence, verbal violence, depression, anxiety, or suicidal ideation. 
While these individuals presented with one type of initial symptom, many of them 
experienced a variety of cognitive deficits and behavioral/mood changes throughout their 
lives (Figure 2). Most of the group who presented initially with behavior/mood symptoms 







Figure 2: Clinical Manifestations of CTE (adapted from Stern 2013) 
This figure shows the clinical features and course displayed by initial clinical 
presentation for subjects diagnosed with CTE.10 
 
This study was further expanded upon by Mez et al. in 2015, who analyzed the 
clinical features of 202 deceased American football players. 32 They used retrospective 
clinical data obtained by telephone and online questionnaires to analyze symptoms of 
American football players who were pathologically diagnosed with either mild (Stage I or 
II) or severe (Stage III or IV) CTE. They found that behavioral or mood symptoms were 
present in 100% of severe cases and 85% of mild cases. Specifically, they found that 
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impulsivity and hopelessness were the two most common behavioral/mood symptoms in 
both mild and severe cases. In addition to behavioral/mood symptoms, they also found 
cognitive symptoms in 85% of mild cases and 95% of severe cases. Memory impairment 
was also the most common cognitive symptom found in Mez’s study (Figure 2). 
Additionally, this study found that motor symptoms were present in 75% of severe CTE 
cases with the most common complaint being gait instability/slowness being the most 
common complaint.  
Many of the presenting symptoms of CTE can also be confused with other 
neurodegenerative disorders. For example, the most common presenting cognitive 
symptom, memory impairment, could easily lead to a diagnosis of AD rather than CTE. 
Another disease that could be confused with CTE is frontotemporal dementia (FTD), 
which can initially present with behavioral changes. However, FTD usually presents with 
disinhibited speech/behavior and inappropriate speech, which are all rare symptoms in 
those with CTE. The most common motor symptom in severe CTE cases is gait 
instability/slowness which can be easily confused with Parkinson’s Disease.10  
The two studies by Mez and Stern further highlight the difficulty in 
recognizing/distinguishing this disease from others. Individuals can present with multiple 
variations of the disease including behavior/mood, cognitive, and motor function 
symptoms. This strengthens the need for an in vivo way of diagnosing patients so that 
clinicians can be treat the correct neurodegenerative disease. While they were consistent 
with some of the original research on clinical presentations of boxers with CTE, there 
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needs to be further research to truly determine the true prevalence and severity of theses 
clinical presentations of CTE in athletes.  
 
Treatment 
Currently, there is no definitive treatment for CTE. However, our understanding 
of the pathogenesis of CTE could lead to methods by which to inhibit it. There is a “two-
hit” mechanism, which involves acetylation and phosphorylation, that leads to 
accumulation of p-tau. Researchers are looking at ways to inhibit this pathway. Brandon 
et. al found that endoplasmic reticulum (ER) stress, oxidative stress, and 
neuroinflammation contribute to the accumulation of p-tau. Reducing this stress and 
inflammation is a possible way to limit the progression of p-tau accumulation and 
potentially treat this disease. One proposed way to inhibit this progression is through the 
use of docosahexaenoic acid (DHA), an omega-3 fatty acids shown to reduce ER stress.45 
Another study by Lagraouie et al. investigated the effects of NSAIDs, specifically 
salsalate, on mice with post-traumatic brain injuries. They found that there was a 
significant reduction of neuro-inflammation and increased neuroprotection and 
neurogenesis in mice who underwent salsalate treatment following a TBI. While this 
study did not use subjects with CTE pathology specifically, it may lead to further testing 
in those patients. This treatment strategy has also been shown to be effective in other 
neurodegenerative diseases. Salicylate inhibition of the enzyme p300 lysine 
acetyltransferase activity has been shown to prevent tau acetylation in AD, which also 




Synthesis of Existing Research 
One potential risk factor for CTE that has not been studied in depth is the effect of 
cognitive reserve. Cognitive reserve (CR) is defined as an individual brain’s ability to 
cope with insult, such as trauma, neurodegenerative disease, or the normal effects of 
ageing. 47 In other words, CR may have a protective effect by reducing the clinical 
severity of certain neuropathologies or brain damage. There is supporting evidence that 
CR can affect how people’s brains respond to these changes. CR has been measured 
based on different epidemiologic factors, including socioeconomic status (income, 
occupational attainment), educational attainment and leisure activity. It has also been 
measured using other methods such as using IQ and literacy.48  
AD, a disease of similar pathology to CTE, was one of the first diseases studied in 
the context of CR. One study analyzed the effects of education and occupational 
attainment on the onset of clinical dementia. They found that subjects with less than 8 
years of total formal education were at a 2.2 times higher risk of developing dementia 
than individuals with more years of education. In this same study they also found that 
lower occupational attainment was associated with a 2.25 times greater risk of developing 
dementia compared to higher attainment.20 A few years later this same research group 
analyzed the effects of leisure activities, another proxy for CR, on AD pathology. They 
asked about participation of 13 different leisure activities using greater than 6 activities as 
the high participation mark. They found that individuals with a high participation in these 
activities had a reduced risk of dementia by 38%.49 The biggest study to date is a 
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systematic review of 22 cohort studies including more than 29,000 subjects using 
different measures of CR and analyzing their effects on AD. This study found that 
education, occupation, premorbid IQ, and mentally stimulating leisure activities all had a 
significant effect on the incidence of dementia. They used this data to conclude that the 
higher cognitive reserve groups had a decreased incidence of dementia by 46%, 
suggesting a protective effect.50  
Due to the similarities in pathology between AD and CTE, one research group has 
suggested a similar correlation of CR to CTE. They published a study in 2016 in The 
Journal of Neuropsychiatry and Clinical Neurosciences (JNCN). They provided 
preliminary evidence on the effects of CR with the clinical manifestations of CTE. Their 
study included 25 former professional football players diagnosed with CTE stage III or 
IV on autopsy. They used retrospective next of kin interviews via telephone and online 
surveys to gain demographic, clinical, and athletic data on the subjects. For clinical 
symptoms, the researchers specifically asked questions about the initial onset of 
cognitive, behavioral, and mood symptoms. They used occupational and educational 
attainment as the two measures of CR. Educational attainment was defined by number of 
years of formal education. Occupational attainment was defined as high or low based on 
definitions of the U.S. Department of Labor’s Dictionary of Occupational Titles. High 
attainment included professional, technical, and managerial positions. After controlling 
for duration of football played, the authors found that greater occupational attainment had 
a significant correlation with a later onset of initial symptoms by an average of 10 years 
when compared to individuals with low occupational attainment. Individuals with low 
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occupational attainment had an average age of onset of 48.8 (SE=3.72) for cognitive 
symptoms and 37.37 (SE=5.09) for behavioral/mood symptoms. Subjects with high 
occupational attainment had an average age of onset of 60.74 (SE=2.78, p=0.02) for 
cognitive symptoms and 53.58 (SE=3.92, p=0.02) for behavioral/mood symptoms. Their 
study did not show a significant effect for years of education on symptom onset in either 
category (p>0.05). 
This study had multiple limitations. They only had 25 subjects that had a history 
of participating in one professional sport. They also only contained subjects diagnosed 
with pathological stage III/IV CTE. This limited the generalizability of the findings as 
well as the power. Future studies should expand on this by: including a greater number of 
individuals; from different sports; those with varying levels of participation in sports; and 
those with different stages of CTE. Another limitation is that this studied relied on 
retrospective data. They collected subjects’ clinical symptoms based on next of kin 
interviews, which is likely to have some recall bias. Also, this study may include 
selection and ascertainment biases, since family members may be more likely to donate 
the brain of a family member if they were symptomatic. Finally, this study only included 
two measures of CR, educational and occupational attainment. While these have been 
shown to be reliable measures of CR, future research could benefit from including 
additional measures of CR such as IQ, literacy, leisure activities and socioeconomic 
status. 
This study is the first to suggest an effect of cognitive reserve on the clinical 
manifestations of CTE. But there are still some significant gaps in knowledge in this area. 
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Future studies can expand upon the data from this preliminary study in a couple of ways. 
First, they should include additional measurements that have been shown to contribute to 
an individual’s CR. Second, it should expand its criteria to include more subjects from 






This research study will be a retrospective cohort study of male subjects with a history of 
repetitive brain injury in athletes who have been diagnosed with CTE on autopsy. It will 
analyze the effect of CR on the clinical manifestations of CTE and this project will 
organize subjects into different cohorts based on prior sport participation.  
 
Project population and sampling 
The subjects for this project will include former athletes of varying sports that 
have been diagnosed with CTE based on neuropathological findings. This study will use 
the brains donated to the Boston University-Veteran’s Affairs-Concussion Legacy 
Foundation Brain Bank (BU-VA-CLF), the single largest CTE repository in the world, 
housing approximately 70% of the CTE cases worldwide.51 This brain bank contains 315 
brains that have been diagnosed with CTE. Inclusion criteria will be any brain that has 
neuropathological findings of CTE on autopsy based off of the current definition of CTE 
as set by the NINDS and NIBIB in 2016.8 The brain must also be of a former athlete who 
has participated in a sport that has risk of repetitive brain injury. Participation in football, 
hockey, lacrosse, wrestling, rugby, or soccer will be included in our study. Brains that 
have evidence of any concurrent neuropathological disease or acute catastrophic brain 
injury will be excluded in order to reduce any effects these diseases may have on clinical 
manifestations of CTE. Specifically brains that show evidence of AD, Parkinson’s, Lewy 
body dementia, ALS, MS, corticobasal degeneration, frontotemporal dementia, and prion 
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disease on autopsy will not be used for this study. Brains that belonged to subjects with 
no prior sport participation will also be excluded, even if they have evidence of CTE. We 
want to specifically analyze the effects of CR on clinical manifestations in individuals 
who have a shared history of repetitive brain injury in athletic participation and have been 
diagnosed with CTE.  
The maximum sample size for this study will be 315, the number of 
pathologically confirmed cases of CTE in the BU-VA-CLF brain bank. However, this 
sample size is unrealistic as we expect to lose subjects due to not meeting eligibility 
criteria and lack of participation from next of kin. In the Alosco et al. study, most of their 
exclusions were due to neuropathological criteria (stages I/II) or history of participation 
in another sport, both of which we will be including in our study.21 Therefore, we 
estimate we would still have at least 200 subjects in our study. This sample size would 
give our study 80% power to detect an effect size of 0.398 standard deviations with an 
alpha of 0.05. 
 
Exposure 
In this study, subjects will be grouped into cohorts based on level of CR determined by 
the Lifetime of Experiences Questionnaire (LEQ). A total score less than the median for 
this group of individuals will qualify as low CR and a score above the median will 




They will be further separated based on specific sport participation history. If a 
subject participated in multiple sports throughout their lifetime, they will be grouped into 
the cohort of the sport with the longest time of exposure. If they have participated in 
multiple sports for an equal amount of time, they will be grouped into the multi-sport 
participation cohort. Only participation in athletics at the high school level or above will 
be considered for this study. The sports we will be using for our study include football, 
hockey, soccer, lacrosse, wrestling, and rugby. 
 
Project variables and Measurement Tools 
In order to measure CR, next of kin will be sent an online version of the LEQ.52 This 
questionnaire was developed in 2007 to measure the complex mental activity across a 
lifetime in patients with dementia and was shown to be a reliable measure of CR. It 
includes questions about formal education, occupational attainment, and social/leisure 
activities. Formal education is measured in points based on years of educations after high 
school. Occupation was assigned points based on guidelines from the Australian Standard 
Classification of Occupations. Leisure/social activities was measured by asking an 
individual how often they participated in certain activities throughout their life. The mean 
LEQ score across a lifetime for patients with dementia was 75.5 (SD=20).52 More details 
about the scoring system of this survey can be found in the Appendix. 
 In addition to the LEQ, next of kin will complete another online survey that asks 
about other demographic data about the subjects. This survey will ask about their age, 
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athletic participation history (what specific sports, duration), and past medical history 
(looking for diagnoses of other neurodegenerative diseases). 
 Phone interviews will be conducted by neurologists in order to measure the onset 
and severity of clinical symptoms. Specifically, they will ask about the age of onset of 
symptoms and the severity, while classifying them as cognitive or behavioral/mood 
(Table 1).  
 
Table 1. Classification of Symptoms. This table illustrates the most common symptoms 
associated with CTE and how to characterize them. 
Cognitive Symptoms Behavioral Symptoms Mood Symptoms 
• Memory Impairment 
• Executive Dysfunction 
• Attention Difficulties 
• Lack of Concentration 
• Language Impairment 
• Visuospatial Difficulties 
• Explosivity 
• Impulse Control Deficits 
• Physical Violence 
• Verbally Violent 
• Disinhibited Speech 
• Disinhibited Behavior 











Age of onset will be measured in years. Severity of the clinical symptoms will be 
determined by the type of clinical symptom the subject experienced. They will be 
categorized into very mild, mild, moderate, and severe based on the staging system 
introduced by Mckee in 2013 (Table 2). If a subject experiences multiple symptoms, the 
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symptom with the highest severity stage will be used for analysis. These interviews need 
to be performed by a neurologist in order to accurately characterize the description of the 
symptoms by next of kin and answer any questions they may have. For example, next of 
kin may not understand symptoms of executive dysfunction, the second most common 
cognitive feature of CTE, but a neurologist trained in assessing these types of patients 
would be able to explain the definition and help them characterize the symptoms. 
 
Table 2. Summary of Clinical Symptom Severity/Staging of CTE (adapted from 
Schwab 2018)1 This table illustrates the most common clinical symptoms associated with 
CTE at each stage and level of severity. Symptoms in lower stages can also appear in 
higher stages 
Stage (severity) Clinical Symptoms 
Stage I (very mild) § Headaches 
§ Loss of attention 
§ Loss of concentration 
Stage II (mild) § Depression 
§ Mood Swings 
§ Explosivity 
§ Short-term memory loss 
Stage III (moderate) § Memory loss 
§ Executive dysfunction 
§ Visuospatial abnormalities 
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In order to recruit subjects for our study we will first contact the BU-VA-CLF 
brain bank in Boston, Massachusetts. We will ask to use all of the subjects in their brain 
bank that have been diagnosed with CTE. We will then contact the next of kin for the 
brains to obtain consent for the study. We will also use next of kin in a retrospective 
interview process to gain data about the subjects including demographics, clinical 
symptoms, and athletic exposure history.  
 
Data collection 
The study will utilize both phone interviews and online survey to collect data. The 
neurologists who are performing the telephone interviews will manually enter the clinical 
characteristics into a Microsoft Excel file during each interview. For our online survey 
about demographics and athletic history we will use Qualtrics online survey software. We 
will also incorporate our LEQ questions into this software. The Qualtrics link will be 
emailed to every next of kin participant. As results are received, student volunteers will 
help to transfer the data from Qualtrics to a Microsoft Excel document. This document 





First, we will perform descriptive statistics to quantify the level of CR in the 
different athletes from each sport. We will calculate and report the mean and standard 
deviation of LEQ scores in each cohort of athletes. 
Two independent sample t tests will be used to look for significant differences 
between level of CR (high vs low) and average age of onset of symptoms. The 
independent variable in this test will be level of CR (high vs low) and the dependent 
variable will be age of onset of symptoms. For this test our alpha will be 0.05 and our 
Confidence Interval will be 0.95. 
We will use the Chi-square goodness-of-fit test to look for a significant difference 
in the level of CR (high vs low) and severity of clinical manifestations. The independent 
variable will remain CR (high vs low) and the dependent variable will be severity of 
clinical manifestation (very mild, mild, moderate, severe). For this test our alpha will be 
0.05 and our Confidence Interval will be 0.95. 
We will also utilize a simple linear regression with R-squared analysis to show 
the relationship between age of onset of CTE symptoms and level of CR measured by the 
LEQ score. For this test our independent variable will be LEQ score and our dependent 
variable will be age of onset of symptoms. Our alpha will be 0.05 and our Confidence 
Interval will be 0.95.  
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Timeline and resources 
This project is expected to be completed within a six month timeframe. We will first need 
to obtain consent from the BU-VA-CLF brain bank to use their specimens. Once this is 
completed we will spend 1 month contacting next of kin for consent and scheduling 
phone interviews. After consent is obtained by the brain bank and next of kin, we will 
spend the following 3 months performing telephone interviews and sending out the online 
surveys/questionnaires. Before sending out the LEQ we will contact Dr. Valenzuela, the 
developer of the questionnaire, to obtain consent for use in our study. The telephone 
interviews that include asking about clinical symptoms will be performed by a 
neurologist. We expect to recruit at least 5 neurologists from Boston Medical Center to 
help with this process. We will contact the chief of neurology for help with the 
recruitment. If our goal of at least 200 subjects is reached, they will perform at least 40 
interviews each within 3 months. After the data is collected, we will use one primary 
statistician with a team of student workers to collect/transfer the data and perform the 
necessary statistical analyses and create the proper figures. This process is expected to 
take no more than 1 month. We will use Boston University undergraduate or graduate 
students for this work.  We will contact the School of Public Health at Boston University 
to recruit a primary biostatistician for this study. That will leave 1 month to finalize the 




Institutional Review Board 
We will submit the proper documents to the Boston University Medical Campus 
Institutional Review Board (BUMC IRB) for the ethical review of human subjects 
research prior to the start of project. Our proposal will be submitted electronically to the 
Integrated Network for Subject Protection in Research II for expedited board review. 
This research meets the criteria of expedited review in the following ways: it has not been 
previously reviewed and approved by the IRB; it presents no more than minimal risk to 
human subjects and involves procedures that fit into category 5; the research is not 
classified; the identification of subjects will not put them at risk of criminal or civil 
liability or be socially or economically damaging. We will not conduct any research until 






This project aims to advance the understanding of CTE, but there are many limitations to 
this study that must be addressed. First, study data will be collected retrospectively 
through phone interviews and online surveys with next of kin. Thus, there is the 
possibility of recall bias during the data collection process. Next of kin may have 
difficulty remembering certain details about the subjects’ history, especially details about 
their clinical symptoms and the age of onset. Even though recall bias may influence this 
project, a study in 1995 on dementia using retrospective information concluded that it is 
possible to obtain accurate information about clinical characteristics of dementia from 
informants such as close relatives.53 Despite those findings, our data would still be more 
accurate if the subjects were able to answer these questions about themselves, especially 
questions about leisure time/activities. A prospective longitudinal study of athletes in 
contact sports who agree to donate their brains for autopsy upon death would mitigate 
these limitations. However, this type of study would be infeasible. It would require 
recruitment of many more subjects, since we cannot expect every subject with a history 
of athletic participation to have CTE pathology.  It could also take more than 30 years to 
complete since the average age of symptom onset has been shown to be between 34 and 
59 years old depending on the symptom type.10  
Another limitation to our study is that our subjects are from the BU-VA-CLF 
CTE brain bank. This sample could be formed from ascertainment bias, due to the fact 
that families are likely to donate to a CTE brain bank only if their loved ones were 
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symptomatic. This reduces the ability to evaluate the possibility that CR could reduce or 
eliminate clinical symptoms of CTE in the presence of pathological findings. This bias 
could be reduced by using a different non-CTE brain bank in future studies. We used the 
BU-VA-CLF brain bank for convenience as it contains the largest number of CTE cases 
already confirmed on autopsy.  
Despite these limitations, our study does have some key strengths. This is only the 
second study analyzing the association of CR with clinical manifestations of CTE. The 
first study to evaluate this was done in 2016 by Alosco et al.21 Alosco’s study used a 
sample of 25 professional football players with pathologically diagnosed CTE, using only 
stages III/IV. Our study expands upon this sample to include subjects from different 
contact sports, including football, at multiple levels of participation, from high school to 
professional. We also will include stages I and II of pathologically diagnosed CTE, as 
well as stages III and IV. Another key addition to our study is our measure of CR. The 
first study only used occupational and educational attainment as markers for CR. While 
these are two reliable methods to measure CR, they are not the only two measures that 
have been shown to predict CR level. In addition to occupational and educational 
attainment, we will add social/leisure activities measured by the LEQ survey. This will 
allow us to analyze an additional factor that may contribute to CR. Overall, these 






Chronic Traumatic Encephalopathy is a neuropathological disease characterized by the 
accumulation and deposition of hyperphosphorylated tau protein in distinct areas of the 
brain which results in the onset of clinical manifestations. The disease was first 
discovered in boxers in the early 1900s and was eventually found in participants of sports 
associated with repetitive brain trauma, such as football, hockey, rugby, and soccer, as 
well as military veterans with blast exposure history. One of the main hurdles when 
studying this disease is the inability to diagnose CTE in vivo. Many diagnostic 
methodologies are currently being studied to allow scientists and clinicians to better 
understand the true prevalence of the disease and its clinical course. In addition to 
diagnosis, there are other areas of investigation that may affect CTE’s clinical course and 
potential treatment strategies. This study evaluates one of those areas, the effect of 
cognitive reserve on the clinical manifestations of CTE. Certain proxies of CR have 
already been shown to have a significant correlation with the age of onset of clinical 
symptoms of CTE. Our study will be able to expand upon that analysis by including 
additional groups of people at risk for CTE and by analyzing more aspects that can 
contribute to CR.  
 
Clinical and/or public health significance 
The results of this study can lead to significant advances in the prevention and treatment 
of CTE. If increased CR is shown to have a significant positive effect on the clinical 
manifestations of CTE, then strategies can be developed to increase CR in populations 
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most at-risk for the development of CTE. One way to do this is to encourage clinicians to 
provide patient education on how they can increase CR. For example, a primary care 
physician can educate a former college hockey player on ways to increase CR through 
increased leisure/lifestyle activities that lead to higher reserve. Some of these lifestyle 
activities highlighted in the LEQ include membership to social or charity groups, 
diversity of reading materials, and frequency of seeing family members. Providers can 
also explain the benefits and encourage these at-risk populations to pursue more formal 
education and/or occupations that lead to higher reserve.  
At the professional level, institutions like the NFL, NHL, and MLS can increase 
their efforts in providing resources to former professional athletes in areas such as 
financial management and preparing for retirement from the sport. They can better help 
to prepare these athletes for life after sports, which would ideally lead to increased 
occupational attainment and increased leisure activities. Other governing bodies, such as 
the National Collegiate Athletic Association (NCAA), can also implement some of these 
methods to increase CR in their athletes. College athletes could be required to take a class 
about CTE, which would not only provide them with a better understanding of the 
disease but could teach them ways to increase their CR throughout their lifetime.  
 Lastly, the results of this study could lead to a potential strategy in treating CTE. 
Not only can CR be used to prevent or delay the effects of the disease but it can be used 
as part of the treatment plan once CTE is diagnosed in vivo. The benefits of cognitive 
training to prevent further cognitive decline in patients diagnosed with Parkinson’s 
disease has been shown.54 Future studies can use this data to examine whether similar 
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Education scores in the Young Adulthood sub-section were calculated in the following 
manner: clerical or short business courses were scored 4 points; 3 year trade or technical 
college course 6 points, 4 year trade apprenticeship 8 points; 3 or 4 year college courses 8 
points; undergraduate university courses 10 points; postgraduate Masters 8 points; 
postgraduate doctorate 10 points; other post graduate courses 4 points per year of study. 
A cumulative education score for the Young Adulthood section was summed and then 
normalized1 with the Young Adulthood non-specific subscores. As indicated above, 
together these two scores contributed a third of the overall LEQ score. If an individual 
completed a formal educational course outside his or her Young Adulthood period, an 
equivalent number of points was added to the LEQ total in the relevant life-stage section 
as an adjustment. 
Occupation scores were calculated for the 30–35, 35–40, 45–50, 50–55, 55–60 
and 60–65 year age ranges. The main occupation pursued in each age bracket (in terms of 
years worked) was classified according the Australian Standard Classification of 
Occupations (ASCO (ABS Australian Bureau Of Statistics, 1997)) guidelines: 
professional occupations such as engineers, doctors, lawyers and so forth are classified 
1.0; semi-professionals such as teachers and police as 2.0; skilled tradespersons 3.0; 
unskilled tradespersons 4.0 and so forth with unskilled clerical staff in the ultimate ASCO 
category (8.0). Each occupational category was first inverted, so that occupations with 
greater cognitive and managerial responsibilities scored higher, and then summed. A 
cumulative occupational score for the Mid Life section was summed and then normalized 
with the Mid Life nonspecific subscores (as a whole group). As indicated in the previous 
section, together these two scores contributed a third of the overall LEQ score. If an 
individual was continuing in paid employment beyond 65 years of age then an equivalent 
number of points was added to the Late Life section as an adjustment. 
Late life-specific questions focused on social, leisure and information-seeking 
behaviour. The following questions formed the Specific Late Life score, with each 
affirmative response in the direction of greater complexity/frequency given an equivalent 
value out of five (unless indicated otherwise below): 
i. Reside alone or with partner (not coded) 
ii. Membership of social groups 
iii. Membership of charity groups 
iv. Frequency of seeing family members 
v. Frequency and diversity of participating in events and entertainment 
(frequency x diversity recorded and scaled out of 5) 
vi. Behavoiral analysis of typical day – this items was recorded into a 10-
point scale based on the diversity of activities listed (25 items to choose 
from; 0–4=1, 5–7=2, 8–9=3, 10–11=4, 12=14=5, 15–16=6, 17–18=7, 19–
20=8, 21–22=9, 23+=10 
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vii. Diversity of information sources 
viii. Diversity of reading materials 
 
A cumulative activity score for the Late Life specific section was summed and then 
normalized with the Late Life non-specific subscores (as a whole group). As indicated 
previously, together these two scores contributed a third of the overall LEQ score. 
 
Non-specific life stage questions: each life stage asked a standard set of 8 questions 
relating to participation in a diverse number of leisure, mental activity, artistic and fitness 
pursuits (only the first 7 were used to derive the LEQ total). Each was scored out of 5 and 
summed to produce a theoretical maximum of 35. 
 
1 Note on normalization.  
As this was the first iteration of the LEQ, there was not a prior reason to weight scores from any one of the Young 
Adulthood, Mid Life or Late Life subsections more than another. Thus scores from each Life stage was weighted 33. 
3% towards the overall LEQ total. Furthermore, within each Life stage score, there were items from the Specific and 
Non-Specific domains and there was no compelling reason to weight scores from one domain over the other. Given 
scores from the Non-Specific domain in each Life stage had an absolute maximum of 35, and tended towards a mean of 
around 12, and scores from the Specific domain varied more widely, we applied a different Normalisation Factor to 
each individual’s Life stage Specific score so that at the group level they approximated a mean of 12. Thus, for the 
Young Adulthood Specific score a normalization factor of 0. 7 was applied, for the Mid Life Specific score 0. 25, and 
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